Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.41 |
| ▸ | RHEB | Q15382 | 4/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668854 | 0.82 | P2RX7 (0.35) | P2RX7AHR | |
| SCHEMBL16746112 | 0.78 | AHR (0.35) | P2RX7RHEBAHR | |
| SCHEMBL27683825 | 0.77 | AHR (0.42) | P2RX7RHEBAHRNR4A2 | |
| SCHEMBL8529419 | 0.74 | AXL (0.48) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL28906650 | 0.74 | RHEB (0.40) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL27051547 | 0.73 | RHEB (0.44) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL18402851 | 0.73 | P2RX7 (0.41) | P2RX7RHEB | |
| SCHEMBL8527598 | 0.73 | P2RX7 (0.39) | P2RX7RHEBAHRF7LTA4H | |
| SCHEMBL31038049 | 0.73 | P2RX7 (0.41) | P2RX7RHEB | |
| SCHEMBL26773498 | 0.73 | GABRA1 (0.48) | P2RX7AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| CN-1129937-A | Indoline derivatives as 5HT2C antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-08-28 | — | — | CN | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | P2RX7 395/4885RHEB 2672/4885AHR 3033/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | P2RX7 395/4885RHEB 2672/4885AHR 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.